Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ARCT-032

mRNA medicine · Protein replacement: CFTR gene mutation · developed by Arcturus Therapeutics

Phase 2 Most advanced trial
ARCT Developer
1 Registered trials

What is ARCT-032?

ARCT-032 is a CFTR mRNA formulated in lipid nanoparticles. It delivers messenger RNA encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, intended to supply the protein in people with cystic fibrosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
mRNA medicine
Targets
CFTR gene mutation (biomarker)
Mechanism
Protein replacement: CFTR gene mutation
Therapy area
Respiratory
Developer
Arcturus Therapeutics, Inc. (ARCT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06747858 Phase 2 Cystic Fibrosis Recruiting ARCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CFTR Gene MutationCystic Fibrosis

More from Arcturus Therapeutics

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ARCT page.

Follow ARCT, the company behind ARCT-032

See ARCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARCT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.